Hecht Beth sold $134K of XERS
Hecht Beth (See Remarks) sold 16,666 shares of Xeris Biopharma Holdings, Inc. (XERS) at $8.01 ($0.13M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
An officer’s open-market sale is disclosed, including trade size, price, and post-transaction holdings, under a pre-arranged 10b5-1 plan.
Market read
Traders may treat this as low-signal information because it is a 10b5-1 sale, not a discretionary trade or a corporate event.
What to watch
The article provides no context on total insider holdings, prior sale cadence, or whether other insiders filed around the same time, limiting inference.
Background
The article is a SEC Form 4 insider transaction disclosure for Xeris Biopharma Holdings, Inc.
Ticker impact
Xeris Biopharma Holdings disclosed an insider open-market sale by officer Hecht Beth of 16,666 shares at $8.0135 on Aug 3.
Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.
The filing is an S (sale) transaction and explicitly states a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.
Market effects
No clear sector read-through from a single 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider sales can coincide with periods of perceived valuation risk, so traders may still watch for follow-on selling patterns.
Key entities
- issuerXeris Biopharma Holdings, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHecht Beth
Officer who sold 16,666 shares in an open-market transaction.
